The therapeutic effect of monocyte chemoattractant protein-I delivered by an electrospun scaffold for hyperglycemia and nephrotic disorders

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 985-993

  Yong, Cai ^b   Wang, Zhengxin ^a   Zhang, Xing ^c   Shi, Xiaomin ^a   Ni, Zhijia ^a   Fu, Hong ^a   Ding, Guoshan ^a   Fu, Zhiren ^a   Yin, Hao ^a,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Diabetes; Electrospinning; Islet transplantation; MCP 1

Indexed keywords

C PEPTIDE; CREATININE; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT PROTEIN; TISSUE SCAFFOLD; CCL2 PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CELL POPULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; MOUSE; NANOFABRICATION; NEPHROSIS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; PHYSICAL CHEMISTRY; TISSUE ENGINEERING; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENETICS; HUMAN; METABOLISM; NANOMEDICINE; PATHOPHYSIOLOGY; TISSUE SCAFFOLD; TRANSGENIC MOUSE;

ANIMALS; BLOOD GLUCOSE; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG DELIVERY SYSTEMS; HUMANS; HYPERGLYCEMIA; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NANOMEDICINE; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84896804813     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S55812     Document Type: Article

References (43)

1. Gregg EW, Cheng YJ, Saydah S, et al. Trends in death rates among US adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care. 2012;35(6): 1252-1257.
2. Porte D Jr, Schwartz MW. Diabetes complications: why is glucose potentially toxic? Science. 1996;272(5262):699-700.
3. Gackler D, Jakel S, Fricke L, Reinsch B, Fischer F. [Diabetes and kidneys]. Dtsch Med Wochenschr. 2013;138(18):949-955. German.
4. Mathis D, Vence L, Benoist C. Beta-cell death during progression to diabetes. Nature. 2001;414(6865):792-798.
5. Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes. 2002;51(7):2148-2157.
6. Robertson RP. Islet transplantation as a treatment for diabetes - a work in progress. N Engl J Med. 2004;350(7):694-705.
7. Ricordi C, Strom TB. Clinical islet transplantation: advances and immunological challenges. Nat Rev Immunol. 2004;4(4):259-268.
8. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes. 1997;46(11):1907-1910.
9. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol. 2005;77(5):587-597.
10. Zhang X, Xu Y, Thomas V, Bellis SL, Vohra YK. Engineering an antiplatelet adhesion layer on an electrospun scaffold using porcine endothelial progenitor cells. J Biomed Mater Res A. 2011;97(2): 145-151.
11. Zhang X, Thomas V, Xu Y, Bellis SL, Vohra YK. An in vitro regenerated functional human endothelium on a nanofibrous electrospun scaffold. Biomaterials. 2010;31(15):4376-4381.
12. Zhang X, Thomas V, Vohra YK. Two ply tubular scaffolds comprised of proteins/poliglecaprone/polycaprolactone fibers. J Mater Sci Mater Med. 2010;21(2):541-549.
13. Thomas V, Zhang X, Vohra YK. A biomimetic tubular scaffold with spatially designed nanofibers of protein/PDS bio-blends. Biotechnol Bioeng. 2009;104(5):1025-1033.
14. Zhang X, Thomas V, Vohra YK. In vitro biodegradation of designed tubular scaffolds of electrospun protein/polyglyconate blend fibers. J Biomed Mater Res B Appl Biomater. 2009;89(1):135-147.
15. Thomas V, Zhang X, Catledge SA, Vohra YK. Functionally graded electrospun scaffolds with tunable mechanical properties for vascular tissue regeneration. Biomed Mater. 2007;2(4):224-232.
16. Yin H, Gao M, Leoni L, Han H, Zhang X, Fu Z. The therapeutic role of monocyte chemoattractant protein-1 in a renal tissue engineering strategy for diabetic patients. PloS One. 2013;8(2):e57635.
17. Panee J. Monocyte chemoattractant protein 1 (MCP-1) in obesity and diabetes. Cytokine. 2012;60(1):1-12.
18. Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J. 2012;53(2):258-261.
19. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 2008;28(11):1950-1959.
20. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol. 2001;69(4):513-521.
21. Graves DT, Jiang Y, Valente AJ. The expression of monocyte chemoattractant protein-1 and other chemokines by osteoblasts. Front Biosci. 1999;4:D571-D580.
22. Piemonti L, Leone BE, Nano R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes. 2002;51(1):55-65.
23. Kriegel MA, Rathinam C, Flavell RA. Pancreatic islet expression of chemokine CCL2 suppresses autoimmune diabetes via tolerogenic CD11c+ CD11b+ dendritic cells. Proc Natl Acad Sci U S A. 2012;109(9):3457-3462.
24. Park SY, Wang X, Chen Z, et al. Optical imaging of pancreatic beta cells in living mice expressing a mouse insulin I promoter-firefly luciferase transgene. Genesis. 2005;43(2):80-86.
25. Hara M, Wang X, Kawamura T, et al. Transgenic mice with green fluorescent protein-labeled pancreatic beta-cells. Am J Physiol Endocrinol Metab. 2003;284(1):E177-E183.
26. Grossman EJ, Lee DD, Tao J, et al. Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice. PloS One. 2010;5(1):e8749.
27. Meinel AJ, Germershaus O, Luhmann T, Merkle HP, Meinel L. Electrospun matrices for localized drug delivery: current technologies and selected biomedical applications. Eur J Pharm Biopharm. 2012;81(1):1-13.
28. Ji W, Sun Y, Yang F, et al. Bioactive electrospun scaffolds delivering growth factors and genes for tissue engineering applications. Pharm Res. 2011;28(6):1259-1272.
29. Sill TJ, von Recum HA. Electrospinning: applications in drug delivery and tissue engineering. Biomaterials. 2008;29(13):1989-2006.
30. Tibbitt MW, Anseth KS. Dynamic microenvironments: the fourth dimension. Sci Transl Med. 2012;4(160):160ps24.
31. Prewitz M, Seib FP, Pompe T, Werner C. Polymeric biomaterials for stem cell bioengineering. Macromol Rapid Commun. 2012;33(17): 1420-1431.
32. Baker BM, Chen CS. Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues. J Cell Sci. 2012;125(Pt 13): 3015-3024.
33. Yannas IV. Emerging rules for inducing organ regeneration. Biomaterials. 2013;34(2):321-330.
34. Edalat F, Sheu I, Manoucheri S, Khademhosseini A. Material strategies for creating artificial cell-instructive niches. Curr Opin Biotechnol. 2012;23(5):820-825.
35. Chung S, King MW. Design concepts and strategies for tissue engineering scaffolds. Biotechnol Appl Biochem. 2011;58(6):423-438.
36. Urbschat A, Obermuller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers. 2011;16 Suppl 1:S22-S30.
37. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30(1):49-59.
38. Cirillo P, Sautin YY, Kanellis J, et al. Systemic inflammation, metabolic syndrome and progressive renal disease. Nephrol Dial Transplant. 2009;24(5):1384-1387.
39. Roh JD, Sawh-Martinez R, Brennan MP, et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci U S A. 2010;107(10):4669-4674.
40. Ohtsuki K, Hayase M, Akashi K, Kopiwoda S, Strauss HW. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: an autoradiographic study. Circulation. 2001;104(2):203-208.
41. Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta. 2010;411(21-22):1570-1579.
42. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313-326.
43. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev. 2004;25(6): 971-1010.